Valuation: Indivior

Market Cap 4.91B 4.29B 3.94B 3.67B 6.96B 467B 7.08B 47.41B 18.37B 229B 18.43B 18.03B 790B P/E 2026 *
12.7x
P/E 2027 * 11.1x
Enterprise Value 4.96B 4.34B 3.98B 3.71B 7.04B 472B 7.16B 47.94B 18.58B 232B 18.63B 18.23B 798B EV / Sales 2026 *
3.94x
EV / Sales 2027 * 3.44x
Free-Float
94.38%
Yield 2026 *
-
Yield 2027 * -
Change 5-day change 1-year change 3-year change Capi.($)
+0.09%+1.57% - - 4.91B
+1.61%+7.25%+55.21%+162.12% 1,063B
+3.10%+6.81%+68.14%+60.12% 611B
+3.45%+6.67%+35.97%+92.10% 444B
+4.17%-0.96%+26.12%+20.22% 324B
+4.94%+3.39%+39.92%+40.14% 285B
+2.42%+1.60%+30.06%+44.59% 283B
+2.47%+5.18%-24.80%-38.67% 219B
+2.74%+5.20%+25.03%+64.95% 195B
+3.22%+4.93%+16.53%+69.38% 156B
Average +2.88%+2.83%+30.24%+57.22% 397.85B
Weighted average by Cap. +2.88%+4.16%+40.97%+82.55%

Financials

2026 *2027 *
Net sales 1.26B 1.1B 1.01B 941M 1.78B 120B 1.81B 12.15B 4.71B 58.74B 4.72B 4.62B 202B 1.31B 1.14B 1.05B 979M 1.86B 125B 1.89B 12.64B 4.9B 61.07B 4.91B 4.8B 210B
Net income 414M 362M 333M 310M 588M 39.46B 598M 4B 1.55B 19.35B 1.56B 1.52B 66.69B 473M 413M 379M 354M 671M 45.02B 682M 4.57B 1.77B 22.08B 1.78B 1.74B 76.08B
Net Debt 54.5M 47.62M 43.73M 40.78M 77.31M 5.19B 78.62M 527M 204M 2.54B 205M 200M 8.77B -403M -352M -324M -302M -572M -38.4B -582M -3.9B -1.51B -18.84B -1.51B -1.48B -64.91B
Logo Indivior
Indivior Pharmaceuticals, Inc. is a global pharmaceutical company engaged in developing medicines to treat substance-use disorders (SUD). The Company provides treatment for addiction, including SUBLOCADE (buprenorphine extended-release) injection for subcutaneous use, a long-acting injectable (LAI) for opioid use disorder and OPVEE (Nalmefene) nasal spray for opioid overdose recovery. Its core products include SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, OPVEE (nalmefene), and SUBLOCADE. SUBOXONE Film is a buprenorphine and naloxone sublingual film. SUBOXONE Tablet is a buprenorphine and naloxone sublingual tablet. SUBUTEX Tablet is a buprenorphine sublingual tablet. SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, and SUBLOCADE are treatments for opioid use disorder (OUD). In addition to its commercially available products, its product pipeline includes two drug candidates for the treatment of OUD. It sells its products in the United States and in other selected areas of the world.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-